Table 1.
Clinicopathological features between four molecular subtypes in 31 BA patients.
| Variables | Autoimmune subtype (N=10) |
Inflammatory subtype (N=5) |
Virus infection-related subtype (N=7) |
Oxidative stress subtype (N=9) |
p value | Effect size | Power |
|---|---|---|---|---|---|---|---|
| Gender | |||||||
| Male | 6 (60.0%) | 3 (60.0%) | 3 (42.9%) | 4 (44.4%) | 0.844 | 0.163 | 0.844 |
| Female | 4 (40.0%) | 2 (40.0%) | 4 (57.1%) | 5 (55.6%) | |||
| Birth weight (g) | 3262.00 ± 494.97 | 3026.00 ± 673.26 | 3454.29 ± 500.63 | 3240.00 ± 478.04 | 0.582 | 0.271 | 0.982 |
| Surgery weight (g) | 4845.00 ± 939.70 | 4030.00 ± 690.65 | 5328.57 ± 986.09 | 4866.67 ± 1127.22 | 0.186 | 0.438 | 0.998 |
| Surgery age (day) | 57.3 ± 28.27 | 40.4 ± 14.01 | 78.43 ± 26.68 | 66.33 ± 48.949 | 0.288 | 0.475 | 1.000 |
| AST (U/L) | 210.19 ± 100.02 | 142.24 ± 94.23 | 269.27 ± 106.25 | 285.93 ± 157.83 | 0.162 | 0.454 | 0.999 |
| ALT (U/L) | 135.68 ± 71.39 | 82.12 ± 50.90 | 191.07 ± 85.91 | 187.10 ± 138.42 | 0.185 | 0.438 | 0.998 |
| r-GGT (U/L) | 758.42 ± 608.38 | 469.84 ± 496.75 | 505.77 ± 267.23 | 469.13 ± 564.21 | 0.591 | 0.268 | 0.982 |
| TBIL (μmol/L) | 150.63 ± 84.83 | 140.65 ± 28.32 | 191.26 ± 80.75 | 165.56 ± 64.79 | 0.533 | 0.288 | 0.985 |
| DBIL (μmol/L) | 103.77 ± 68.30 | 87.94 ± 31.89 | 139.26 ± 55.54 | 112.04 ± 41.04 | 0.403 | 0.335 | 0.992 |
| IBIL (μmol/L) | 46.86 ± 24.03 | 52.71 ± 21.24 | 51.99 ± 28.73 | 53.93 ± 22.53 | 0.927 | 0.130 | 0.972 |
| TBA (μmol/L) | 150.29 ± 106.45 | 82.41 ± 20.59 | 142.98 ± 41.06 | 126.49 ± 44.07 | 0.342 | 0.359 | 0.994 |
| LSM | 13.05 ± 4.27 | 6.77 ± 1.53 | 15.00 ± 6.57 | 10.63 ± 3.65 | 0.022* | 0.648 | 1.000 |
| Clinical phenotypes | |||||||
| Isolated | 5 (50.0%) | 4 (80.0%) | 7 (100.0%) | 7 (77.8%) | 0.244 | 0.324 | 0.621 |
| Embryonal | 4 (40.0%) | 1 (20.0%) | 0 (0.0%) | 2 (22.2%) | |||
| Cystic | 1 (10.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |||
| CMV-IgM | |||||||
| Positive | 1 (10.0%) | 0 (0.0%) | 4 (57.1%) | 1 (11.1%) | 0.032* | 0.525 | 0.636 |
| Negative | 9 (90.0%) | 5 (100.0%) | 3 (42.9%) | 8 (88.9%) | |||
| Ishak fibrosis score | |||||||
| 1-2 | 3(30.0%) | 4(80.0%) | 2(28.6%) | 4(44.4%) | 0.620 | 0.267 | 0.790 |
| 3-4 | 5(50.0%) | 1(20.0%) | 4(57.1%) | 4(44.4%) | |||
| 5-6 | 2(20.0%) | 0(0.0%) | 1(14.3%) | 1(11.1%) | |||
| Recurrent cholangitis | |||||||
| Yes | 2 (20.0%) | 1 (20.0%) | 2 (28.6%) | 3 (33.3%) | 0.943 | 0.134 | 0.956 |
| No | 8 (80.0%) | 4 (80.0%) | 5 (71.4%) | 6 (66.7%) | |||
| NLS at last follow-up | |||||||
| Yes | 7 (70.0%) | 4 (80.0%) | 4 (57.1%) | 5 (55.6%) | 0.777 | 0.192 | 0.859 |
| No | 3 (30.0%) | 1 (20%) | 3 (42.9%) | 4 (44.4%) | |||
| COJ at 6 months | |||||||
| Yes | 5 (50.0%) | 3 (60.0%) | 2 (28.6%) | 3 (37.5%) | 0.687 | 0.222 | 0.822 |
| No | 5 (50.0%) | 2 (40.0%) | 5 (71.4%) | 5 (62.5%) | |||
BA, biliary atresia; AST, aspartate transaminase; ALT, alanine transaminase; r-GGT, gamma glutamyl transpeptidase; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin; TBA, total biliary acid; LSM, liver stiffness measurement; NLS, natural liver survival; COJ, clearance of jaundice.